表紙
企業レポート

PharmaPoint:HIV−−現在・将来の市場参入企業

PharmaPoint: HIV - Current and Future Players

発行 GlobalData 商品コード 263602
出版日 ページ情報 英文 71 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
PharmaPoint:HIV−−現在・将来の市場参入企業 PharmaPoint: HIV - Current and Future Players
出版日: 2013年01月31日 ページ情報: 英文 71 Pages
概要

当レポートでは、世界のHIV関連市場における既存企業および新規参入企業について分析し、市場全体の将来展望や促進・抑制要因、現在・将来の競争動向、主要企業のプロファイル(企業概要、事業展開、財務状況、SWOT分析)、市場全体と各企業の将来展望などを調査・考察して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場の見通し

  • 世界市場
    • 予測
    • 促進・阻害要因:世界市場の課題

第4章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の傾向
  • 企業プロファイル
    • Gilead
    • ViiV Healthcare
    • AbbVie (Abbott)
    • Merck
    • Janssen(J&Jの子会社)
    • Bristol-Myers Squibb
    • 日本たばこ産業

第5章 付録

図表一覧

目次
Product Code: GDHC1004FPR

Abstract

Summary

GlobalData has released its pharma report, "PharmaPoint: HIV - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing HIV Market. The report identifies and analyses the key companies shaping and driving the global HIV market. The report provides insight into the competitive HIV landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for HIV
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of the HIV sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving the HIV Market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global HIV market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Gilead
    • 4.3.2. ViiV Healthcare
    • 4.3.3. AbbVie (Abbott)
    • 4.3.4. Merck
    • 4.3.5. Janssen (a Subsidiary of J&J)
    • 4.3.6. Bristol-Myers Squibb
    • 4.3.7. Japan Tocacco

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. HIV Prevalence
    • 5.4.2. Percent Drug-Treated Patients
    • 5.4.3. Drugs Included in Each Therapeutic Class
    • 5.4.4. Launch and Patent Expiry Dates
    • 5.4.5. General Pricing Assumptions
    • 5.4.6. Individual Drug Assumptions
    • 5.4.7. Generic Erosion
    • 5.4.8. Pricing of Pipeline agents
  • 5.5. Physicians and Specialists Included in this Study
    • 5.5.1. Survery of Prescribing Physicians
  • 5.6. About the Authors
    • 5.6.1. Authors
    • 5.6.2. Epidemiologists
    • 5.6.3. Global Head of Healthcare
  • 5.7. About GlobalData
  • 5.8. Contact Us
  • 5.9. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for HIV, 2012-2022
  • Table 2: Global HIV Market - Drivers and Barriers, 2012-2022
  • Table 3: Key Companies in the HIV Market, 2012
  • Table 4: Gilead's HIV Therapy Portfolio Assessment, 2012
  • Table 5: Gilead SWOT Analysis, 2012
  • Table 6: ViiV Healthcare's HIV Therapy Portfolio Assessment, 2012
  • Table 7: ViiV Healthcare SWOT Analysis, 2012
  • Table 8: AbbVie's HIV Therapy Portfolio Assessment, 2012
  • Table 9: AbbVie SWOT Analysis, 2012
  • Table 10: Merck's HIV Therapy Portfolio Assessment, 2012
  • Table 11: Merck SWOT Analysis, 2012
  • Table 12: Janssen's HIV Therapy Portfolio Assessment, 2012
  • Table 13: Janssen SWOT Analysis, 2012
  • Table 14: BMS' HIV Therapy Portfolio Assessment, 2012
  • Table 15: BMS SWOT Analysis, 2012
  • Table 16: Japan Tobacco's HIV Therapy Portfolio Assessment, 2012
  • Table 17: Japan Tobacco SWOT Analysis, 2012
  • Table 18: Key Launch Dates
  • Table 19: Key Patent Expiries
  • Table 20: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for HIV by Region, 2012-2022
  • Figure 2: Company Portfolio Gap Analysis in HIV, 2012-2022
Back to Top